Mental health app Lissun plows $3M into AI integrations
Indian mental health platform Lissun has raised $2.5 million in a pre-Series A funding round led by RPSG Capital Ventures.
The startup plans to use the new funding to integrate AI into a suite of digital mental health solutions aimed at businesses, schools, and families of children with neurodevelopmental disorders. The new funding will also be used to expand services and grow the team.
Proceeds from this new investment round bring the total investment to $5 million. Lissun last raised more than $1 million in seed funding in September of the previous year.
Asan Medical Clinic prescribes locally approved vision loss treatment drug DTx for the first time
Asan Medical Center (AMC), one of South Korea’s largest hospitals, has started prescribing a Korean-made digital treatment for visual impairment caused by stroke.
The mobile-based application Vivid Brain provides training to enhance users’ responses to visual stimuli through virtual reality.
AMC formalized this solution in September, five months after the South Korean government’s approval. The third is for local DTx.
AMC Professor Kang Dong-hwa, who developed Vivid Brain with Nunaps (a local company he founded), is now planning to expand his company’s DTx to hospitals domestically and internationally.
Neurofet’s latest collaborative research predicts Alzheimer’s disease risk
South Korean medical imaging AI company Neurofet has announced a new partnership to develop a new Alzheimer’s disease diagnostic platform.
The company said in a statement that it will collaborate with local biotechnology company Alivio, which develops treatments for neurodegenerative diseases.
They plan to integrate Neurofet’s MRI-based image analysis software with Alivio’s blood-based Alzheimer’s disease diagnostic test to detect early on people with Alzheimer’s disease-positive amyloid beta protein deposits in their brains. be.
Their solution aims to make Alzheimer’s disease testing more accessible and reduce the need for expensive repeat amyloid PET imaging tests, according to a press release.
The collaboration between Neurophet and Aribio builds on existing research in Phase 3 of Arbio’s global clinical trial of AR1001, an oral Alzheimer’s disease treatment.
In July, Neurophet introduced Neurophet AQUA AD, its latest Alzheimer’s disease treatment prescription and monitoring software.
